Medicare Enrolled
Dr. Mohsin Malik, MD
Medical Oncology · Kissimmee, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Malik from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Malik? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Malik
Dr. Mohsin Malik is a medical oncology in Kissimmee, FL, with 19 years in practice. Based on federal Medicare data, Dr. Malik performed 284,609 Medicare services across 4,890 unique beneficiaries.
Between the years covered by Open Payments, Dr. Malik received a total of $11,501 from 70 pharmaceutical and/or device companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Malik is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 6% volume in FL$ $11,501 industry payments
Medicare Practice Summary
Medicare Utilization ↗284,609
Medicare services
Top 6% in FL for medical oncology
4,890
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~14,979 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 66,750 | $1 | $3 |
| Iron infusion (Feraheme) | 42,840 | $0 | $4 |
| Iron sucrose injection (Venofer) | 26,800 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 24,200 | $43 | $137 |
| Filgrastim injection (Nivestym) for white blood cells | 21,360 | $0 | $1 |
| Filgrastim injection (Zarxio) for white blood cells | 19,380 | $0 | $2 |
| Azacitidine chemotherapy injection | 19,200 | $0 | $4 |
| Anti-nausea injection (aprepitant) | 18,850 | $1 | $5 |
| Epoetin alfa injection (Procrit) for anemia | 9,540 | $6 | $23 |
| Immune globulin infusion (Gammagard) | 5,128 | $36 | $108 |
| Denosumab injection (Prolia/Xgeva) | 4,560 | $18 | $51 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,564 | $26 | $116 |
| Dexamethasone injection (steroid) | 3,561 | $0 | $3 |
| Complete blood count (CBC) with differential | 3,407 | $8 | $29 |
| Blood draw (venipuncture) | 3,094 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,150 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,181 | $95 | $339 |
| Injection, leucovorin calcium, per 50 mg | 927 | $3 | $12 |
| Drug injection, under skin or into muscle | 802 | $10 | $69 |
| Office visit, established patient (20-29 min) | 612 | $66 | $239 |
| Injection, fluorouracil, 500 mg | 605 | $2 | $7 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 546 | $3 | $205 |
| Administration of chemotherapy into vein, 1 hour or less | 544 | $97 | $378 |
| Injection of additional new drug or substance into vein | 511 | $12 | $61 |
| Anti-nausea injection (ondansetron/Zofran) | 440 | $0 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 426 | $47 | $189 |
| Injection, carboplatin, 50 mg | 415 | $2 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 311 | $22 | $84 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 248 | $54 | $206 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 212 | $1 | $6 |
| Injection, zoledronic acid, 1 mg | 195 | $7 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 177 | $15 | $56 |
| Injection, diphenhydramine hcl, up to 50 mg | 173 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 162 | $49 | $178 |
| Administration of chemotherapy into vein, each additional hour | 143 | $22 | $79 |
| Administration of additional new drug or substance into vein using push technique | 134 | $42 | $170 |
| Infusion, normal saline solution , 1000 cc | 131 | $2 | $7 |
| Initial hospital admission, high complexity | 128 | $137 | $556 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 116 | $17 | $59 |
| Injection of drug or substance into vein | 113 | $28 | $156 |
| Prothrombin time test (blood clotting) | 104 | $4 | $15 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 96 | $3 | $11 |
| Infusion into a vein for hydration, 31-60 minutes | 88 | $24 | $156 |
| Infusion into a vein for hydration, each additional hour | 76 | $10 | $42 |
| New patient office visit (45-59 min) | 75 | $123 | $453 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 72 | $15 | $56 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 71 | $126 | $637 |
| Office visit, established patient, complex (40-54 min) | 58 | $134 | $474 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $25 | $89 |
| Automated urinalysis | 48 | $2 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 46 | $1 | $7 |
| New patient office visit, complex (60-74 min) | 42 | $162 | $585 |
| Hospital follow-up visit, high complexity | 42 | $94 | $285 |
| New patient office visit (30-44 min) | 41 | $83 | $298 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 24 | $115 | $467 |
| Transitional care management services for problem of high complexity | 24 | $214 | $722 |
| Initial hospital admission, moderate complexity | 15 | $103 | $377 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
40.8% high complexity
55.9% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,501
Total received (2018-2024)
Avg $1,643/year across 7 years
Top 40% in FL for medical oncology
70
Companies
531
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,759 (84.9%)
Other
Charitable contributions, space rental, and other categories
$1,017 (8.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$725 (6.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,550
2023$3,024
2022$1,823
2021$750
2020$241
2019$821
2018$292
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,379
Celgene Corporation
$1,286
Janssen Biotech, Inc.
$863
PFIZER INC.
$579
Astellas Pharma US Inc
$560
Merck Sharp & Dohme LLC
$523
E.R. Squibb & Sons, L.L.C.
$371
GENZYME CORPORATION
$346
Gilead Sciences, Inc.
$336
Daiichi Sankyo Inc.
$324
Eisai Inc.
$306
GlaxoSmithKline, LLC.
$260
Amgen Inc.
$255
Seagen Inc.
$228
Genentech USA, Inc.
$216
AstraZeneca Pharmaceuticals LP
$216
Lilly USA, LLC
$190
Incyte Corporation
$186
ABBVIE INC.
$182
Octapharma USA, Inc.
$180
Bayer Healthcare Pharmaceuticals Inc.
$157
SOBI, INC
$155
Mayne Pharma Inc.
$152
Takeda Pharmaceuticals U.S.A., Inc.
$138
ARRAY BIOPHARMA INC
$124
BeiGene USA, Inc.
$118
TerSera Therapeutics LLC
$116
JAZZ PHARMACEUTICALS INC.
$96
Seattle Genetics, Inc.
$96
Regeneron Healthcare Solutions, Inc.
$84
EMD Serono, Inc.
$82
Pharmacosmos Therapeutics Inc.
$79
Boehringer Ingelheim Pharmaceuticals, Inc.
$78
Clovis Oncology, Inc.
$73
Alexion Pharmaceuticals, Inc.
$72
Pharmacyclics LLC, An AbbVie Company
$71
Kite Pharma, Inc.
$69
PharmaEssentia USA Corporation
$69
Global Blood Therapeutics, Inc.
$62
Agios Pharmaceuticals, Inc.
$58
Karyopharm Therapeutics Inc.
$52
EISAI INC.
$44
Bayer HealthCare Pharmaceuticals Inc.
$44
Sumitomo Pharma America, Inc.
$43
Alnylam Pharmaceuticals Inc.
$43
Blueprint Medicines Corporation
$40
Stemline Therapeutics Inc.
$38
PUMA BIOTECHNOLOGY, INC.
$36
CSL Behring
$34
UCB, Inc.
$29
ImmunoGen, Inc.
$27
Apellis Pharmaceuticals, Inc.
$22
Myriad Genetic Laboratories, Inc.
$22
MorphoSys, US Inc.
$21
Mirati Therapeutics, Inc.
$20
EUSA Pharma (US) LLC
$20
RECORDATI_RARE_DISEASES_INC.
$20
SpringWorks Therapeutics, Inc.
$20
Myovant Sciences Inc.
$19
CTI BioPharma Corp.
$19
Tempus AI, Inc
$18
Sirtex Medical Inc
$17
TAIHO ONCOLOGY, INC.
$17
Puma Biotechnology, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$16
ADC Therapeutics America, Inc.
$15
Ipsen Biopharmaceuticals, Inc
$14
SECURA BIO, INC.
$14
Legend Biotech USA Inc.
$14
Sobi, Inc
$14
Top 3 companies account for 30.7% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · AYVAKIT · Afstyla · Alecensa · Aliqopa · BAVENCIO · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CAMZYOS · CARVYKTI · COPIKTRA · COSELA · CYRAMZA · Cimzia · DARZALEX · DOPTELET · DORYX · Doptelet · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Elahere · Empaveli · Enhertu · Erleada · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · JEVTANA · Jivi · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · Morphabond ER · NERLYNX · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PANHEMATIN · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SKYRIZI · SOMATULINE DEPOT · Stivarga · Sylvant · TAGRISSO · TALTZ · TALVEY · TASIGNA · TIVDAK · TREMFYA · TUKYSA · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · Vanflyta · Venclexta · Vonjo · Vyloy · XOSPATA · XPOVIO · XT CDX · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZIIHERA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
26
Per 100K population
6.4
County median income
$68,711
Nearest hospital
CENTRAL FLORIDA BEHAVIORAL HOSPITAL
8.2 mi
8.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Malik is a mixed practice specialist, with above-average Medicare volume (top 6% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Malik experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Malik performed 66,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Malik receive payments from pharmaceutical companies?
Yes. Dr. Malik received a total of $11,501 from 70 companies across 531 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Malik's costs compare to other medical oncologys in Kissimmee?
Dr. Malik's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Malik) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Kissimmee
Browse medical oncologys in Kissimmee ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology